Helsinki, 9 March 2015 at 8:00 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive brain
stimulation, announces the publication of its 2014 Annual Report. These
documents are available on the "Investor Relations" section of the Company's
website at www.nexstim.com.
The Annual Report contains the Report of the Board of Directors, the Financial
Statements and Consolidated Financial Statements and the Auditor's Report.
A copy of the Annual Report is attached to this release.
Nexstim Plc
Janne Huhtala, CEO
For further information please visit www.nexstim.com or contact:
Nexstim +358 40 8615046
Janne Huhtala, Chief Executive Officer janne.huhtala@nexstim.com
UB Capital Oy (Certified Adviser) +358 9 2538 0225
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan nexstim@consilium-comms.com
About Nexstim Plc
Nexstim, formed in 2000 and based in Finland, is a medical technology company
aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its
technology in brain diagnostics with the Navigated Brain Stimulation (NBS)
system as the first and only FDA-cleared and CE-marked navigated Transcranial
Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and
speech cortices. Based on the same technology platform, the company has
developed a device for stroke therapy called Navigated Brain Therapy (NBT(®)).
In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in
the US aiming to demonstrate the effectiveness of NBT(®) and gain FDA clearance
for commercialisation in post-acute stroke therapy in the US. Nexstim's shares
are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more
information please visit www.nexstim.com.
[HUG#1900141]
